Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Raf pathway inhibitors in oncology.

Bollag G, Freeman S, Lyons JF, Post LE.

Curr Opin Investig Drugs. 2003 Dec;4(12):1436-41. Review.

PMID:
14763129
2.

Raf kinase inhibitors in oncology.

Strumberg D, Seeber S.

Onkologie. 2005 Feb;28(2):101-7. Review.

PMID:
15665559
3.

Raf: a strategic target for therapeutic development against cancer.

Beeram M, Patnaik A, Rowinsky EK.

J Clin Oncol. 2005 Sep 20;23(27):6771-90. Review.

PMID:
16170185
4.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

6.

Regulation of c-Raf-1: therapeutic implications.

Beeram M, Patnaik A, Rowinsky EK.

Clin Adv Hematol Oncol. 2003 Aug;1(8):476-81. Review.

PMID:
16258435
7.

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

Thompson N, Lyons J.

Curr Opin Pharmacol. 2005 Aug;5(4):350-6. Review.

PMID:
15955734
8.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
9.

B-Raf kinase inhibitors for cancer treatment.

Li N, Batt D, Warmuth M.

Curr Opin Investig Drugs. 2007 Jun;8(6):452-6. Review.

PMID:
17621874
10.

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Montagut C, Settleman J.

Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Review.

PMID:
19217204
11.

Raf kinase as a target for anticancer therapeutics.

Sridhar SS, Hedley D, Siu LL.

Mol Cancer Ther. 2005 Apr;4(4):677-85. Review.

13.

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.

Herrera R, Sebolt-Leopold JS.

Trends Mol Med. 2002;8(4 Suppl):S27-31. Review. Erratum in: Trends Mol Med 2002 May;8(5):243.

PMID:
11927284
14.

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Friday BB, Adjei AA.

Clin Cancer Res. 2008 Jan 15;14(2):342-6. doi: 10.1158/1078-0432.CCR-07-4790.

15.

Design and discovery of small molecules targeting raf-1 kinase.

Lowinger TB, Riedl B, Dumas J, Smith RA.

Curr Pharm Des. 2002;8(25):2269-78. Review.

PMID:
12369855
16.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
17.

[Signal transduction inhibitor].

Ueda Y, Saijo N.

Gan To Kagaku Ryoho. 2001 May;28(5):591-600. Review. Japanese.

PMID:
11383206
18.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
19.

Discovery of a novel Raf kinase inhibitor.

Lyons JF, Wilhelm S, Hibner B, Bollag G.

Endocr Relat Cancer. 2001 Sep;8(3):219-25. Review.

20.

Ras/Raf signalling and emerging pharmacotherapeutic targets.

Kolch W.

Expert Opin Pharmacother. 2002 Jun;3(6):709-18. Review.

PMID:
12036410

Supplemental Content

Support Center